| Literature DB >> 30539527 |
Wan-Chi Hsiao1, Shian-Ying Sung1,2,3, Leland W K Chung4, Chia-Ling Hsieh5,6.
Abstract
Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.Entities:
Keywords: Adenoviral vector; HSV-tk enzymatic assay; Osteonectin promoter construction; Prostate cancer; Suicide gene therapy
Mesh：
Substances：
Year: 2019 PMID： 30539527 DOI： 10.1007/978-1-4939-8922-5_3
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745